| Literature DB >> 35153144 |
Michael C Onyema1, Eftychia E Drakou2, Georgios K Dimitriadis3.
Abstract
Paraneoplastic syndromes denote rare but notable phenomena caused by the tumour mediated release of bioactive substances. Peptide and non-peptide hormone causes are explored with a particular focus on pathogenesis, symptoms, diagnosis and treatment. Early detection and management of paraneoplastic syndromes can improve morbidly and mortality; definitive treatment remains effective surgical or anti-tumour therapies. Pituitary autoimmunity may provide a novel presentation of paraneoplastic syndromes for which further research is warranted.Entities:
Keywords: cytokines; endocrine; hormones; paraneoplastic syndrome; peptides; pituitary autoimmunity
Mesh:
Year: 2022 PMID: 35153144 DOI: 10.1016/j.beem.2022.101621
Source DB: PubMed Journal: Best Pract Res Clin Endocrinol Metab ISSN: 1521-690X Impact factor: 4.690